Pelthos Therapeutics Inc Asset Turnover Ratio (PTHS), as of first quarter 2026, current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Pelthos Therapeutics Inc   (NYSEAMER: PTHS)
 

Pelthos Therapeutics Inc Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

Pelthos Therapeutics Inc asset turnover ratio, the ability of Pelthos Therapeutics Inc 's assets to generate revenue in the first quarter 2026, increased sequentially to 0.28 in the first quarter (Mar 31 2026), PTHS's balance sheet remain strong.

Within sector Pelthos Therapeutics Inc achieved the highest asset turnover ratio. While asset turnover ranking remained unchanged in the First Quarter 2026 compared to previous quarter at no. .

Asset Turnover Ratio Definition


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PTHS Asset Turnover Ratio (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Asset Change 15509.67 % 9186.32 % 5808.39 % -68.4 % -77.4 %
Y / Y Revenue Change - - - - -
Asset Turnover Ratio (TTM) 0.28 0.26 0.23 - -
PTHS's Total Ranking # # # # #
Seq. Asset Change 11.86 % 0.56 % 15265.25 % -9.69 % -33.45 %
Seq. Revenue Change 16.16 % 26.78 % - - -



Asset Turnover Ratio Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #

Asset Turnover Ratio Statistics
High Average Low
0 0 0
 




PTHS Company Profile • Back to PTHS Efficiency Comparisons • Compare PTHS Asset Turnover Ratio to its Competitors



Companies with similar Asset Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Mar 31 2026 Assets at quarter ending Mar 31 2026
Lifecore Biomedical Inc   0.53 $ 125.080  Millions$ 234.434  Millions
Cvrx inc   0.53 $ 57.909  Millions$ 108.853  Millions
Enovis Corp  0.53 $ 2,275.853  Millions$ 4,280.440  Millions
Icu Medical Inc  0.53 $ 2,156.379  Millions$ 4,068.639  Millions
Bridgebio Pharma Inc   0.53 $ 579.958  Millions$ 1,096.362  Millions
Artivion Inc   0.53 $ 458.098  Millions$ 866.000  Millions
Intuitive Surgical Inc   0.53 $ 10,582.100  Millions$ 20,021.175  Millions
Bristol myers Squibb Company  0.53 $ 48,482.000  Millions$ 92,019.750  Millions
Brookdale Senior Living Inc   0.52 $ 3,145.058  Millions$ 6,001.057  Millions
Gilead Sciences Inc   0.52 $ 29,736.000  Millions$ 57,388.750  Millions
Clearpoint Neuro Inc   0.52 $ 40.614  Millions$ 78.597  Millions
Merck and Co Inc   0.51 $ 65,768.000  Millions$ 128,155.000  Millions
Carlsmed Inc   0.51 $ 55.386  Millions$ 109.256  Millions
Novavax inc   0.50 $ 596.338  Millions$ 1,184.028  Millions
Ultragenyx Pharmaceutical Inc   0.50 $ 669.708  Millions$ 1,331.178  Millions
Amgen Inc   0.50 $ 45,369.000  Millions$ 90,282.000  Millions
Cryo cell International Inc   0.50 $ 31.281  Millions$ 62.555  Millions
Envista Holdings Corporation  0.50 $ 2,807.800  Millions$ 5,640.975  Millions
Abbott Laboratories  0.49 $ 45,134.000  Millions$ 91,330.500  Millions
Emergent Biosolutions Inc   0.49 $ 676.800  Millions$ 1,379.275  Millions
Johnson and Johnson  0.49 $ 96,362.000  Millions$ 196,577.250  Millions
American Shared Hospital Services  0.49 $ 28.410  Millions$ 58.332  Millions
Vertex Pharmaceuticals Inc  0.48 $ 12,218.000  Millions$ 25,256.600  Millions
Ceribell Inc   0.48 $ 94.389  Millions$ 195.274  Millions
Fonar Corporation  0.48 $ 105.338  Millions$ 217.926  Millions
Rhythm Pharmaceuticals Inc   0.48 $ 217.165  Millions$ 450.530  Millions
Orthopediatrics Corp  0.48 $ 241.789  Millions$ 501.978  Millions
Ge Healthcare Technologies Inc   0.48 $ 17,475.000  Millions$ 36,414.500  Millions
Boston Scientific Corporation  0.48 $ 20,616.000  Millions$ 43,072.500  Millions
Xenetic Biosciences Inc   0.48 $ 3.190  Millions$ 6.674  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.